



NUCLEABIOMARKERS

PRESS RELEASE

For Further Information Contact:

Patrick J. Muraca, Ph.D, MPH, President and CEO

Nuclea Biomarkers, LLC

105 South Street

Pittsfield, MA 01201

Phone: (413) 298-1009

Fax: (413) 298-5114

Email: pr@nucleabiomarkers.com

www.nucleabiomarkers.com

FOR IMMEDIATE RELEASE

NUCLEA BIOMARKERS ANNOUNCES THAT IT HAS RECEIVED NOTIFICATION FROM THE UNITED KINGDOM THAT IT'S DESIGN PATENT APPLICATION ENTITLED "ANITBODY PROTEIN ANALYSIS CHIP" HAS BEEN ALLOWED

Pittsfield, Massachusetts -----April 10, 2006 ----- Nuclea Biomarkers, LLC received notification from the United Kingdom of its intention to issue a Certificate of Registration for its Design Patent. We are very pleased concerning the allowance of this patent," stated Patrick J. Muraca, Ph.D., Co-founder, President and CEO, of Nuclea. "Our technology allows Nuclea to accurately, reproducibly and rapidly analyze gene or protein targets, assuring reliable results when analyzing the nucleic acids for the presence of specific proteins.

Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to improve greatly the efficiency of drug discovery research. Using the Company's extensive libraries of genetic, molecular, and outcomes data and data-mining services, research professionals in pharmaceutical and life sciences companies are able to focus time and money on the most promising paths for diagnosing and treating a broad range of diseases.